A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-08. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
==== Less common side effects ==== Because these drugs act on parts of the blood and blood vessels, they tend to have side effects that affect these processes. Aside from problems with hemorrhage and hypertension, less common side effects of these drugs include dry, itchy skin, hand-foot syndrome (tender, thickened areas on the skin, sometimes with blisters on palms and soles), diarrhea, fatigue, and low blood counts. Angiogenesis inhibitors can also interfere with wound healing and cause cuts to re-open or bleed. Rarely, perforations (holes) in the intestines can occur.
Papanicolaou staining, or PAP staining, was developed to replace fine needle aspiration cytology (FNAC) in hopes of decreasing staining times and cost without compromising quality. This stain is a frequently used method for examining cell samples from a variety of tissue types in various organs. PAP staining has endured several modifications in order to become a “suitable alternative” for FNAC. This transition stemmed from the appreciation of wet fixed smears by scientists preserving the structures of the nuclei opposed to the opaque appearance of air dried Romanowsky smears. This led to the creation of a hybrid stain of wet fixed and air dried known as the ultrafast papanicolaou stain. This modification includes the use of nasal saline to rehydrate cells to increase cell transparency and is paired with the use of alcoholic formalin to enhance colors of the nuclei. The papanicolaou stain is now used in place of cytological staining in all organ types due to its increase in morphological quality, decreased staining time, and decreased cost. It is frequently used to stain Pap smear specimens. It uses a combination of haematoxylin, Orange G, eosin Y, Light Green SF yellowish, and sometimes Bismarck Brown Y.
=== Recovery supplements === Common supplements to help athletes recover from exercising include protein and amino acid supplements. The main use for athletes to take dietary proteins are enhance muscle repair and growth. The intake of protein is a part of the nutrient requirements for the normal athlete and is an important component of exercise training. In addition, it aids in performance and recovery. A 2018 meta-review recommended that individuals may take up to 1.6 g/kg/day of protein with a confidence interval spanning from 1.03 to 2.20 so “it may be prudent to recommend ~2.2 g protein/kg/d for those seeking to maximise resistance training-induced gains in FFM.”. FFM is an abbreviation for fat free mass. Dietary protein intake for well-trained athletes should occur before, during and after physical activity as it is advantageous in gaining muscle mass and strength. In healthy individuals with good kidney function there is no evidence that consuming a high protein diet has any deleterious effects. A bountiful protein diet must be paired with a healthy, well-rounded meal plan and regular resistance exercise. Characteristics of this particular diet include the type of exercise, intensity, duration and carbohydrate values of diet. Post-exercise nutrition is an important factor in a nutrition plan for athletes as it pertains to the recovery of the body. Traditionally, sports drinks such as Gatorade and Powerade, are consumed during and after exercise because they effectively rehydrate the body by refueling the body with carbohydrates, minerals and electrolytes.
Sources: en.wikipedia.org
=== Zubrin's planet mastery === In Entering Space: Creating a Spacefaring Civilization, Robert Zubrin suggests another form: his definition of a Type I civilization is described as one that has achieved full mastery of the resources of its planet (global), a Type II of its solar system (interplanetary), and a Type III would have unleashed the full potential of the galaxy (starfaring civilization). Metrics other than pure energy consumption have also been proposed. He ponders the possibility of a Type IV civilization, one that would dominate the universe, noting that there are limits to how minds can connect and interact on a galactic or intergalactic basis. As an example, he mentions that communication from the Galactic Center of the Milky Way galaxy to its edge would take about 50,000 years (since nothing can travel faster than light, according to our understanding of physics).
The Washington Post also followed up with a correction of errors in its earlier report on the Smithsonian acquisition, stating that it incorrectly referred to Ayyadurai as the inventor of electronic messaging; the 'bcc', 'cc', 'to' and 'from' fields existed previously; Ayyadurai had not been honored as the "inventor of email". Writing for Gizmodo, Sam Biddle argued that email was developed a decade before EMAIL, beginning with Ray Tomlinson's sending the first text letter between two ARPANET-connected computers in 1971. Biddle quoted Tomlinson: "[We] had most of the headers needed to deliver the message (to:, cc:, etc.) as well as identifying the sender (from:) and when the message was sent (date:) and what the message was about." Biddle allowed for the possibility that Ayyadurai may have coined the term "EMAIL" and used the header terms without being aware of earlier work, but maintained that the historical record isn't definitive on either point. Biddle wrote that "laying claim to the name of a product that's the generic term for a universal technology gives you acres of weasel room.
During the 1971–72 season, she co-starred as barmaid Ruth in Nichols, a James Garner–led Western, which aired 22 episodes on NBC. During an August 3, 1970, interview on The Dick Cavett Show, Kidder stated that she was ambivalent toward having a film career, and was considering working as a film editor in the future. At this time, she had become an acquaintance of director Robert Altman, and served as an apprentice assisting him in editing Brewster McCloud (1970). She subsequently appeared in "Such Dust As Dreams Are Made On", the first pilot for Harry O, which aired in March 1973. She was a guest star in a 1972 episode of the George Peppard detective series Banacek. After moving to Los Angeles, Kidder was cast opposite Gene Wilder in Quackser Fortune Has a Cousin in the Bronx (1970) as an exchange student in Ireland who becomes the love interest of a poor horse manure collector in Dublin, whom she almost runs over with her car. After filming in Ireland, Kidder relocated to New York City to study acting further. A year later, she returned to California, and was cast in the Brian De Palma film Sisters (1972), which gained notoriety for both the director and Kidder, who as leading lady, portrayed conjoined twins, one of whom is a suspect in a brutal murder. Kidder had been in a relationship with De Palma at the time, and had been roommates with co-star Jennifer Salt in Los Angeles.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.